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Correspondencebe found with this article online at Age-related clonal haemopoiesis 
(ARCH) in healthy individuals was initially 
observed through an increased skewing 
in X-chromosome inactivation [1]. More 
recently, several groups reported that 
ARCH is driven by somatic mutations [2], 
with the most prevalent ARCH mutations 
being in the DNMT3A and TET2 genes, 
previously described as drivers of myeloid 
malignancies. ARCH is associated with an 
increased risk for haematological cancers 
[2]. ARCH also confers an increased risk 
for non-haematological diseases, such as 
cardiovascular disease, atherosclerosis, 
and chronic ischemic heart failure, for 
which age is a main risk factor [3,4]. 
Whether ARCH is linked to accelerated 
ageing has remained unexplored. The 
most accurate and commonly used 
tools to measure age acceleration are 
epigenetic clocks: they are based on 
age-related methylation differences at 
specifi c CpG sites [5]. Deviations from 
chronological age towards an increased 
epigenetic age have been associated with 
increased risk of earlier mortality and age-
related morbidities [5,6]. Here we present 
evidence of accelerated epigenetic age in 
individuals with ARCH.
The Lothian Birth Cohorts (LBCs) 
of 1921 and 1936 are two longitudinal 
studies of ageing [7]. Participants have 
been followed up every ~3 years, each for 
fi ve waves, from the age of 70 (LBC1936) 
and 79 (LBC1921). Participants were 
community dwelling, relatively healthy, 
and mostly lived in the City of Edinburgh 
or its surrounding area when recruited.
Whole-blood DNA methylation levels 
were assessed using the Illumina R786 Current Biology 29, R775–R789, Augus
This is an open access article under the CC BY
HumanMethylation450 BeadChip (Supplemental Experimental Procedures). 
Genomic variants were determined 
in 1,136 LBC participants (n = 870 
from wave 1 at mean age 70 years in 
LBC1936; n = 101 and n = 165 at mean 
ages 79 and 87, respectively, in LBC1921) 
with whole-genome sequencing (WGS) 
and methylation data. WGS data were 
aligned with Burrows-Wheeler Aligner and 
processed for duplicate mapping reads 
with samblaster (genome coverage of 
34.3 reads). Single-nucleotide variants 
and short indels were called with 
MuTect (v3.8) before annotation using 
the Ensembl Variant Effect Predictor 
alongside the Cosmic database of coding 
mutations (v86). ARCH variants were 
classifi ed as per Jaiswal et al. [2].
Epigenetic age acceleration was 
calculated online (https://dnamage.
genetics.ucla.edu/home). We considered 
the Intrinsic Epigenetic Age Acceleration 
(IEAA, hereafter referred to as Horvath 
age acceleration) measure, which is an 
adapted version of the original Horvath 
clock that controls for white blood cell 
proportions [6]. Epigenetic age estimates 
were regressed on chronological age 
to yield age acceleration residuals. 
Linear regression adjusting for sex, 
imputed white blood cell proportions 
(monocytes, natural killer (NK), CD4+ T, 
CD8+ T, and B cells), and methylation 
processing batch was used to determine 
the association between ARCH status 
and Age Acceleration. All analyses were 
conducted in R v3.5.0.
Of the ten most prevalent ARCH 
mutations [2], we had suffi cient sample 
size and sequencing depth to annotate 
the top six in the LBCs. We identifi ed 73 
participants (from 1,136) with ARCH (6%; 
Figure 1A). The gene-specifi c prevalence 
ranged between 1 and 36 cases with 
ARCH-variant allele frequencies ranging 
from 0.034 to 0.677 (Figure 1B). Mutations 
in TET2 were exclusively frameshift and 
mutations detected in JAK2 (all V617F), 
SF3B1 and TP53 were exclusively 
missense. ARCH status was associated 
with a signifi cant increase in Horvath 
age acceleration: the increase was 4.5 
(SE 0.9) years in LBC1936, and 3.7 (SE 
1.2) years in LBC1921 (p = 2.3 x 10-6 and 
2.5 x 10-3, respectively; Figure 1C and 
Table S1). Compared with non-ARCH 
carriers, those with TET2 mutations had 
a 6.1 (SE 2.2) year and 6.4 (SE 1.9) year 
increase in Horvath age acceleration 
in LBC1936 and LBC1921 (p = 0.004 t 19, 2019 © 2019 The Authors. Published by E
 license (http://creativecommons.org/licenses/
and p = 0.001), respectively. Those with DNMT3A mutations had 3.8 (SE 1.2) 
years increase in LBC1936, and 3.0 
(SE 1.9) years in LBC1921 (p = 0.002 and 
p = 0.11), respectively (Figure 1D). These 
effect sizes are much larger than the sex 
differences in Horvath age acceleration, 
which were 1.8 (SE 0.4) years for men in 
LBC1936 (p = 5.1 x 10-5), and 1.0 years 
(SE 0.8) in LBC1921 (p = 0.18) (Figure 1D 
and Table S1). 
We also considered age acceleration 
estimates from four additional epigenetic 
clocks: Extrinsic (Hannum) Epigenetic 
Age (EEAA) [6], PhenoAge [8], GrimAge 
[9] and Zhang Age [10] (Figure 1E,F and 
Figure S1A–F). Briefl y, ARCH status was 
linked to increased EEAA, PhenoAge, 
GrimAge and ZhangAge, acceleration 
in LBC1921 (effect sizes: 1.9 years, 3.7 
years, 2.8 years and 0.8 years with p = 
0.16, 0.014, 9.6 x 10-4, and 3.5 x 10-3, 
respectively). In LBC1936 there was a 
modest association between ARCH and 
increased EEAA and ZhangAge (2.3 years 
and 0.5 years, p = 0.012 and 4.4 x 10-3) 
but no association with PhenoAge or 
GrimAge acceleration (p = 0.32 and 0.99, 
respectively). There was no consistent 
association between ARCH status and 
white cell count proportions across the 
two cohorts: a lower proportion of NK 
cells was linked with ARCH carrier status 
in LBC1936 (odds ratio per SD of cell 
counts, 0.57 95% CI [0.37, 0.84]), while a 
higher B cell proportion was associated 
with ARCH status in LBC1921 (OR 1.37 
[1.01, 1.94]).
We observed associations between 
ARCH and epigenetic age acceleration 
in the independent LBCs of 1921 and 
1936, where the WGS data and the 
DNA methylation data were processed 
together using identical protocols. 
Although we examined multiple 
epigenetic clocks in relation to ARCH 
status, it is possible that the effect 
sizes may vary by the quality control 
approach applied to the methylation data. 
Additional replication from other cohorts 
would further strengthen the magnitude 
and generalisability of the associations. 
Our results could indicate ARCH as an 
underlying cause for systemic ageing, 
explaining its link to non-haematological, 
age-related diseases. 
SUPPLEMENTAL INFORMATION
Supplemental Information includes one fi gure, 
one table and experimental procedures and can lsevier Ltd. 
by/4.0/).
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Figure 1. ARCH variants discovered in Lothian Birth Cohort (LBC) participants and their 
effects on epigenetic age as shown in the Horvath (IEAA) and Hannum (EEAA) clocks.
(A) Oncoplot showing variant types within the ARCH positive subset of the LBC. This subset represents 
73 participants (6% of 1,136 total) where one or more described somatic variants were detected in the 
six most prevalent ARCH-associated genes. (B) Box plot describing the distribution of allele frequencies 
in all detected somatic ARCH variants. Genes with a single variant not shown are TP53 and SF3B1 (allele 
frequencies of 0.089 and 0.257, respectively). The overall distribution of allele frequencies by LBC cohort 
(LBC1921/LBC1936) is also displayed. (C) Scatter plot of Horvath age acceleration (IEAA; years) for 
 individual LBC participants against the allele frequency of their somatic ARCH variant in both LBC1921 
(orange dots, net 3.7 years; p = 2.5 x 10-3) and LBC1936 (green dots, net 4.5 years; p = 2.3 x 10-6) cohorts. 
Density plot highlighting the shift in distribution of Horvath age acceleration between ARCH-positive 
(orange) and -negative participant (turquoise) groups. Non-ARCH carriers (blue dots). (D) Plot showing 
net IEAA in ARCH (with 95% confi dence intervals). The effect of sex (male versus female) on epigenetic 
ageing within the LBC is shown for comparison. (E) Scatter plot showing the Hannum age acceleration 
(EEAA; years) against the allele frequency of ARCH variants in both LBC1921 (orange dots, net 1.9 years; REFERENCES
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p = 0.16) and LBC1936 (green dots, net 2.3 years; 
p = 0.01) cohorts. Density plot highlighting shift 
in distribution of EEAA between ARCH-positive 
(orange) and -negative participant (turquoise) 
groups. Non-ARCH carriers (blue dots). (F) 
Plot showing the net EEAA in ARCH (with 95% 
confi dence intervals). The effect of sex (male 
versus female) on epigenetic ageing within the 
LBC is shown for comparison.
